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Liver Injury as a Surrogate for
Inflammation and Predictor of
Outcomes in COVID-19

Kajali Mishra,1 Sandra Naffouj,1 Sarah Gorgis,2 Hanan Ibrahim,1 Sonika Gill,1 Raef Fadel,1 Abigail Chatfield,3 Amy Tang,3 and
Reena Salgia4

Respiratory failure is the most common cause of death in patients with corona virus disease 2019 (COVID-19). There
have been many investigations to determine predictors of bad outcomes in patients with this illness. Liver enzyme
elevation has been described in hospitalized patients with severe COVID-19; however, little is known about the significance of liver injury regarding outcomes. We conducted a retrospective chart review of 348 patients admitted with
COVID-19 in our quaternary care center. Liver injury on admission was defined based on the laboratory cutoff of
aspartate aminotransferase >35 IU/L and/or alanine aminotransferase >52 IU/L. Patients were divided into two cohorts
based on the presence or absence of liver injury. These cohorts were compared to assess differences in presentation,
complications, and outcomes. The primary outcome was respiratory failure requiring intubation, and the secondary outcome was in-hospital mortality. The presence of new onset liver enzyme elevation on presentation was associated with
increased severity of illness, need for mechanical ventilation, and mortality. Presence of liver injury increased the chance
of acute hypoxic respiratory failure requiring mechanical ventilation by 1.79 times. The degree and timeline of liver
enzyme elevation during hospitalization corresponded with elevations of other inflammatory markers. Conclusion: Liver
injury appears to correlate with the inflammatory syndrome caused by COVID-19, with the degree of liver injury corresponding with severity of inflammation. We suggest early and continued monitoring of liver enzymes as they can be
useful to identify patients who may need early escalation of care. (Hepatology Communications 2021;5:24-32).

C

oronavirus disease 2019 (COVID-19) caused
by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused global alarm.
COVID-19 was declared a pandemic by the World
Health Organization on March 11, 2020. Originally
from Wuhan, China, the virus has since spread to over
187 countries.(1) The rapid influx of information from
many countries has aimed to help clinicians better
understand trends in clinical characteristics, complications, and management strategies.

COVID-19 is primarily a respiratory illness, with
severe acute hypoxic respiratory failure being the
most severe complication.(2) However, observational
studies have also reported cardiac, renal, neurologic,
and gastrointestinal involvement.(3,4) Elevated liver
enzymes have been noted to be common in patients
presenting with COVID-19, with some studies
reporting an incidence up to 53%.(5) More significant
transaminase elevations have been seen in patients
with severe illness compared to mild disease.(6-10)

Abbreviations: ACE-2, angiotensin converting enzyme 2; ACEi, angiotensin converting enzyme inhibitor; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; BMI, body mass index; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; LDH, lactate dehydrogenase;
PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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A proposed hypothesis for this relates to SARSCoV-2 showing an increased angiotensin converting enzyme 2 (ACE-2) receptor affinity, similar to
SARS.(8) ACE-2 receptors are found in abundance in
the liver and biliary system. Notably, liver histology
in patients with COVID-19 has resemblance to liver
biopsy findings in SARS.(8,11) However, the pathophysiology of liver injury caused by the virus is not
well understood. Moreover, the extent of liver injury
and its impact on overall patient outcomes are yet to
be elucidated.
The objectives of this study are to assess potential
differences in demographics, comorbidities, severity,
and outcomes in patients with COVID-19 presenting with liver injury compared to those without liver
injury.

Participants and Methods

MISHRA ET AL.

DATA COLLECTION
Epidemiologic, clinical, laboratory, and treatment
outcome data were obtained from chart reviews. Key
recorded data included signs and symptoms at presentation, medical history, laboratory findings, and treatment measures.

DEFINITION OF VARIABLES
Liver injury was defined as aspartate aminotransferase (AST) >35 IU/L and/or alanine aminotransferase
(ALT) >52 IU/L, based on laboratory cut-off values at
our institution. For comorbid conditions, “respiratory
illness” included patients with chronic obstructive pulmonary disease or asthma; “kidney disease” included
chronic kidney disease or end-stage renal disease; cardiovascular disease included patients with coronary
artery disease or congestive heart failure.

STUDY DESIGN

STATISTICAL ANALYSIS

A retrospective chart review was conducted that
included consecutive patients admitted with laboratory-confirmed SARS-CoV-2 from March 10,
2020, to March 27, 2020. All enrolled patients were
adults, age 18 years and above, who underwent nasopharyngeal swab testing for SARS-CoV-2 RNA
by reverse-transcription polymerase chain reaction
(PCR) in an inpatient setting. Patients were excluded
if insufficient data were available in the electronic
medical record or testing was performed in the
outpatient setting. This study was approved by the
Institutional Review Board of Henry Ford Hospital.
Written informed consent was waived by the ethics
commission of the hospital for patients with emerging infectious diseases.

Categorical variables were described by frequency
and percentages, and continuous variables were
described by the mean, median, and interquartile
range. Patient characteristics were compared using
the Student t test for continuous variables and chisquare or Fisher’s exact tests for categorical variables. Kaplan-Meier survival analysis and log-rank
tests were performed for patients with and without
liver injury. Univariate and multivariate Cox proportional hazards model was used to identify predictors
of need for mechanical ventilation during hospitalization. Receiver operating characteristic curves were
created to predict mortality from the individual laboratory values using logistic regression. A repeated
measures mixed model was created to determine if the
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time to peak AST, ALT, and D-dimer levels differed.
Pearson correlations were run to assess the relationships between these three laboratory tests. All statistical analyses were performed using SAS 9.4 (SAS
Institute, Cary, NC). For all analyses, P ≤ 0.05 was
considered statistically significant.

Results

A total of 366 inpatients tested positive for SARSCoV-2 by nasopharyngeal PCR during the study
period. Due to missing liver biochemistry tests on
admission, 18 patients were excluded, leaving a
study cohort of 348 patients for analysis. Patients
were divided into two cohorts based on the presence (cohort 1) or absence (cohort 2) of liver injury,
as defined by AST >35 IU/L and/or ALT >52 IU/L.
In the overall cohort (n = 348), the average age was
61.5 ± 15.2 years, 50.3% were women, 74.4% were
African Americans, and the average body mass index
(BMI) was 33.6 kg/m2. Characteristics and comparisons of the two cohorts are listed in Table 1.

CLINICAL PRESENTATION
The most common presenting symptoms were
cough in 78% of patients (n = 261), fever in 68.1%
(n = 237), and shortness of breath in 68.7% (n = 239).
Gastrointestinal (GI) symptoms were present in 52.6%
(n = 183) of patients; GI symptoms included diarrhea
(28.7%), anorexia (28.7%), nausea (25.3%), vomiting
(15.2%), and abdominal pain (16.1%). Additional
reported signs and symptoms included chills (42.8%),
myalgias (41.7%), nasal congestion (21.3%), headache (16.1%), loss of smell (2.3%), and loss of taste
(0.6%). Clinical symptoms on presentation were not
significantly different between cohort 1 and cohort 2
(Table 1).

NEW ONSET LIVER INJURY
Patients with new onset liver injury (cohort 1,
n = 184 [52.8%]) were compared to patients without liver injury (cohort 2, n = 164 [47.1%]). There
were no patients with baseline elevations of liver
enzymes. Patients with liver injury had a mean age
of 62.7 ± 14.7 years, with approximately 50% being
over the age of 65. Patients in cohort 1 were more
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commonly men (58.2% vs. 40.2%; P = 0.001), and
there was no difference in race or BMI between the
two cohorts.
Regarding comorbidities, patients presenting
with liver injury were more likely to have a history
of cardiovascular disease compared to those without liver injury (29.3% vs. 19.6%; P = 0.047), but
there was no significant difference in the presence
of hypertension (74.5% vs. 75%), diabetes (45.7%
vs. 47%), and kidney disease (54.4% vs. 46.3%). In
the overall cohort, information collected on home
medications showed that 37.5% of patients were
on an ACE inhibitor (ACEi) or angiotensin receptor blocker, 33.2% were on aspirin, 22.3% were on
nonsteroidal anti-inflammatory drugs, and 9.1%
were on statins. Following a review of imaging
present before the current hospitalization, 23.5%
of patients had abdominal imaging, with 20.7% of
those patients noted to have some degree of baseline
hepatic steatosis.
Patients with liver injury had significantly higher
levels of total bilirubin, inflammatory markers (lactate
dehydrogenase [LDH], C-reactive protein [CRP],
creatinine phosphokinase [CPK], ferritin, D-dimer),
troponin, and lactate at presentation compared to
those without liver injury (Table 1). AST levels on
admission ranged from 9 to 601 IU/L, while ALT
levels ranged from 4 to 380 IU/L. Peak AST and
ALT levels during hospitalization positively correlated with the peak D-dimer (AST and D-dimer:
r = +0.19, P = 0.0007; ALT and D-dimer: r = +0.29,
P < 0.001). Number of days to peak AST, ALT, and
D-dimer from the day of admission were 5.8, 5.3, and
6 days, respectively (Fig. 1).

TREATMENT AND
COMPLICATIONS
Patients were treated with one or more therapy
during hospitalization. Out of 348 patients, 80.2%
received hydroxychloroquine (n = 279), 79.3% empiric
antibiotics (n = 276), and 64.8% systemic steroids
(n = 225). Regarding experimental therapies, 8%
(n = 28) and 2% (n = 8) of patients received tocilizumab and remdesivir, respectively.
In cohort 1, patients were more frequently treated
with hydroxychloroquine (84.8% vs. 75%; P = 0.03),
systemic steroids (73.4% vs. 55.2%; P = 0.01), empiric
antibiotics (84.2% vs. 73.8%; P = 0.027), tocilizumab
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TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS WITH LIVER INJURY (COHORT 1) AND WITHOUT
LIVER INJURY (COHORT 2)
Variables
I. Total numbert of observations (% of total)

Overall

Cohort 1

Cohort 2

348 (100%)

184 (52.9%)

164 (47.2%)

61.5 ± 15.3

62.7 ± 14.7

60.2 ± 15.8

P Value

II. Demographic characteristic
Age, years, mean ± SD
Sex, number (%)

0.1
0.001

Female

175 (50.3%)

77 (41.8%)

98 (59.8)

Male

173(49.7%)

107(58.1%)

66 (40.2%)

White

47 (13.5%)

24 (13.0%)

23 (14.0%)

Black

260 (74.7%)

136 (73.9%)

124 (75.6%)

Others

41 (11.8%)

24 (13.0%)

17 (10.4%)

<30 kg/m2

133 (38.2%)

66 (35.9%)

67 (40.9%)

30-40 kg/m2

137 (39.4%)

77 (41.8%)

60 (36.6%)

>40 kg/m2

78 (22.4%)

41 (22.3%)

37 (22.6%)

Race, number (%)

0.7

BMI, number (%)

0.6

III. Symptoms at admission, number (%)
Fever

237 (68.1%)

129 (70.1%)

108 (65.9%)

0.5

Cough

261 (75.0%)

142 (77.2%)

119 (72.6%)

0.4

Shortness of breath

239 (68.7%)

129 (70.1%)

110 (67.1%)

0.6

Chills

149 (42.8%)

78 (42.4%)

71 (43.3%)

1.0

Myalgias

145 (41.7%)

75 (40.8%)

70 (42.7%)

0.8

Headache

56 (16.1%)

30 (16.3%)

26 (15.9%)

1.0

Nasal congestion

74 (21.3%)

40 (21.7%)

34 (20.7%)

0.9

8 (2.3%)

5 (2.7%)

3 (1.8%)

0.5

Loss of smell
Gastrointestinal symptoms
Nausea

183 (52.6%)

96 (52.2%)

87 (53.0%)

1.0

88 (25.3%)

44 (23.9%)

44 (26.8%)

0.6

Vomiting

53 (15.2%)

27 (14.7%)

26 (15.9%)

0.9

Abdominal pain

56 (16.1%)

30 (16.3%)

26 (15.9%)

1.0

Anorexia

100 (28.7%)

56 (30.4%)

44 (26.8%)

0.5

2 (0.6%)

2 (1.15%)

0 (0.0%)

0.5

100 (28.7%)

54 (29.3%)

46 (28.0%)

0.9

Hypertension

260 (74.7%)

137 (74.5%)

123 (75.0%)

1.0

Diabetes mellitus

161 (46.3%)

84 (45.7%)

77 (47.0%)

0.9

Cardiovascular disease (CAD or CHF)

84 (24.1%)

36 (19.6%)

48 (29.3%)

0.05

Kidney disease (CKD or ESRD)

175 (50.6%)

99 (54.4%)

76 (46.3%)

0.2

Respiratory illness (COPD or asthma)

112 (32.6%)

56 (30.8%)

56 (34.6%)

0.5

History of liver disease

19 (5.5%)

8 (4.3%)

11 (6.7%)

0.66

Cirrhosis

3 (0.9%)

2 (1.1%)

1 (0.6%)

1.0

37 (10.6%)

17 (9.2%)

20 (12.2%)

0.08

Aspirin

123 (35.3%)

61 (33.2%)

62 (37.8%)

0.4

NSAIDs

63 (18.1%)

41 (22.3%)

22 (13.4%)

0.05

ACEi/angiotensin receptor blockers

80 (21.9%)

41 (25%)

38 (20.7%)

0.4

Statin

147 (42.2%)

72 (39.1%)

75 (45.7%)

0.3

Loss of taste
Diarrhea
IV. Comorbidities, number (%)

Fatty liver on prior imaging
V. Medications, number (%)

VI. Laboratory data, median (interquartile range)
White blood cell count, K/µL
Hemoglobin, g/dL

5.8 (4.2, 7.5)

6.1 (4.6, 7.7)

5.5 (3.9, 7.3)

0.05

13.2 (11.8, 14.4)

13.6 (12.2, 14.6)

12.5 (11.5, 13.9)

<0.001

Neutrophil count, K/µL

4.6 (3.1, 6.7)

4.8 (3.5, 7.2)

4.3 (2.9, 6.2)

0.08

Lymphocyte count, K/µL

0.9 (0.6, 1.3)

0.9 (0.7, 1.2)

0.9 (0.6, 1.3)

0.6
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TABLE 1. Continued
Variables

Overall

Cohort 1

Cohort 2

Platelet count, K/µL

177.0 (144.0, 227.5)

171.0 (142.0, 218.0)

182.5 (148.0, 236.5)

0.1

AST, IU/L, mean (SD)

49.8 (8.9)

71.6 (59.5)

25.3 (6.0)

<0.001
<0.001

ALT, IU/L, mean (SD)

P Value

31.4 (30.5)

43.6 (37.1)

17.8 (9.00)

Maximum AST during admission, IU/L

57.00 (35.00, 100.00)

77.00 (54.00, 116.75)

35.00 (26.00, 57.25)

<0.001

Maximum ALT during admission, IU/L

40.00 (22.00, 77.75)

61.00 (33.00, 92.00)

23.50 (17.75, 48.50)

<0.001
<0.001

Total bilirubin, mg/dL

0.6 (0.4, 0.8)

0.6 (0.5, 0.8)

0.5 (0.4, 0.7)

Albumin, mg/dL

3.5 (3.2, 3.8)

3.5 (3.2, 3.8)

3.5 (3.2, 3.8)

0.6

INR, mean (SD)

1.1 (1.0, 1.2)

1.1 (1.0, 1.2)

1.1 (1.0, 1.2)

0.7
0.001

INR <1

47 (13.5%)

23 (12.5%)

24 (14.6%)

INR ≥1

226 (64.9%)

135 (73.4%)

91 (55.5%)

No value available

75 (21.6%)

26 (14.1%)

49 (29.9%)

PT, seconds

13.70 (13.10, 14.45)

13.70 (13.10, 14.43)

13.60 (12.90, 14.45)

PTT, seconds

32.0 (29.0, 36.5)

32.0 (29.0, 36.0)

32.0 (28.0, 37.0)

0.9

1.3 (1.0, 1.8)

1.4 (1.1, 2.0)

1.2 (0.9, 1.6)

<0.001

<0.25 ng/mL

197 (56.6%)

96 (52.2%)

101 (61.6%)

0.001

>0.25 ng/mL

115 (33.0%)

76 (41.3%)

39 (23.8%)

Lactate, mmol/L

0.805

Procalcitonin, number (%)

36 (10.3%)

12 (6.5%)

24 (14.6%)

LDH, IU/L

No value available

336.0 (253.0, 467.5)

408.5 (326.0, 528.5)

261.0 (219.0, 333.5)

<0.001

Creatinine phosphokinase, IU/L

183.0 (93.0, 441.5)

322.0 (132.0, 644.5)

115.5 (69.3, 218.8)

<0.001

9.2 (4.6, 14.3)

11.4 (6.9, 15.7)

6.1 (2.2, 11.2)

<0.001

Ferritin, ng/mL

537.0 (228.5, 1,181.0)

763.0 (361.0, 1,382.8)

344.0 (144.0, 710.5)

<0.001

D-dimer, µg/mL

1.1 (0.7, 2.1)

1.2 (0.8, 2.9)

1.00 (0.5, 1.5)

<0.001
0.04

CRP, mg/dL

High sensitivity troponin, number (%)
<0.18 ng/L

43 (12.4%)

16 (8.7%)

27 (16.5%)

>0.18 ng/L

288 (82.8%)

161 (87.5%)

127 (77.4%)

17 (4.9%)

7 (3.8%)

10 (6.1%)

No value available
VII. Inpatient complications, number (%)
Thromboembolic event

22 (6.3%)

15 (8.2%)

7 (4.3%)

0.2

Septic shock

66 (19.0%)

44 (23.9%)

22 (13.4%)

0.02

AKI requiring dialysis

24 (7.0%)

16 (8.8%)

8 (5.0%)

0.2

Intensive care unit stay

136 (39.1%)

96 (52.2%)

40 (24.4%)

<0.001

Ventilator-dependent respiratory failure

120 (34.5%)

85 (46.2%)

35 (21.3%)

<0.001

11

14

9

<0.001

Length of stay, mean days
VIII. Inpatient medications, number (%)
Antibiotic use

277 (79.4%)

156 (84.7%)

121 (73.8%)

0.03

Systemic steroids

225 (64.8%)

135 (73.4%)

90 (55.2%)

0.001

Hydroxychloroquine

279 (80.2%)

156 (84.8%)

123 (75.0%)

0.03

32 (9.2%)

23 (12.5%)

9 (5.5%)

0.04

Remdesivir or tocilizumab

Abbreviations: AKI, acute kidney injury; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; PT, prothrombin time; PTT, partial thromboplastin time.

(11.4% vs. 4.3%; P = 0.025), and remdesivir (2.7% vs.
1.8%; P = 0.84) compared to cohort 2.
Patients presenting with new-onset liver injury
were more likely to develop acute kidney injury
requiring initiation of renal replacement therapy
(8.8% vs. 5%; P = 0.24), septic shock (23.9% vs.

28

13.4%; P = 0.018), ventilator-dependent respiratory failure (46.2% vs. 21.3%; P = 0.001), or need
for intensive care unit admission (52.2% vs. 24.4%;
P = 0.001). The length of hospital stay was significantly longer for patients with liver injury (14 days
vs. 9 days; P < 0.001).
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FIG. 1. Relationship between laboratory values and peak levels. (A) Mean number of days to peak AST. (B) Mean number of days to peak
ALT. (C) Mean number of days to peak D-dimer levels. The average time to peak levels do not significantly differ (P = 0.26).

TABLE 2. UNIVARIATE AND MULTIVARIATE
ANALYSIS FOR PREDICTORS OF VENTILATORDEPENDENT RESPIRATORY FAILURE
Variables

HR

95% CI

P Value

Presence of liver injury

2.41

1.63, 3.58

0.001

Age

1.63

1.13, 2.34

0.009

Female

0.45

0.31, 0.66

0.001

Univariate analysis

2

BMI (30-40) kg/m

1.73

1.10, 2.72

0.017

Kidney disease

1.86

1.28, 2.70

0.001

Total bilirubin >1.2 mg/dL

1.84

1.03, 3.28

0.038

ALP >140 IU/L

3.09

1.56, 6.11

0.001

Albumin >3.2 g/dL

0.47

0.32, 0.69

0.001

Leukocytosis

1.06

1.01, 1.12

0.017

Elevated LDH

1.00

1.00, 1.00

0.001

CRP >10 mg/dL

2.47

1.68, 3.63

0.001

Ferritin >500 ng/dL

2.53

1.69, 3.77

0.001

D-dimer >1 µg/dL

1.71

1.15, 2.54

0.008

Procalcitonin >0.25 ng/mL

2.27

1.57, 3.25

0.001

Lactate >1 mmol/L

2.02

1.15, 3.54

0.014

1.79

1.17, 2.73

0.008

Multivariate analysis
Presence of liver injury
Male

1.94

1.31, 2.88

0.001

BMI >40 kg/m2

2.17

1.30, 3.63

0.003

Albumin >3.2 gm/dL

2.12

1.42, 3.15

<0.001

Abbreviations: ALP, alkaline phosphatase; CI, confidence interval;
HR, hazard ratio.

VENTILATOR-DEPENDENT
RESPIRATORY FAILURE
On univariate analysis, liver injury was a predictor for ventilator-dependent respiratory failure, along

with other variables (Table 2). When adjusted for
age, sex, BMI, kidney disease, ferritin, CRP, D-dimer,
alkaline phosphatase, bilirubin, lactate, and albumin,
liver injury remained a significant predictor for ventilator-dependent respiratory failure (Fig. 2; Table 2).

IN-HOSPITAL MORTALITY
At the time of manuscript preparation, 77 out of
348 patients (22.1%) had died. Overall, 26% (n = 48)
of patients died in cohort 1 and 17% (n = 29) of
patients died in cohort 2; 20 patients were still hospitalized, the majority (n = 18) of which were in cohort
1. Outcomes (death or discharge) of these patients
(n = 20) were not available at the time of analysis. For
patients with definitive outcomes (death or discharged
alive), a significantly higher number of patients with
liver injury died compared to those without liver
injury (28.9% vs. 17.9%; P = 0.018) (Fig. 3). Using
logistic regression, increased admission AST levels;
peak AST, peak ALT, and total bilirubin levels; and
decreased albumin levels were individually associated
with increased risk of mortality (Table 3; Fig. 4).

Discussion

In hospitalized patients with COVID-19, the presence of new-onset liver enzyme elevation on initial
blood testing was associated with an increased severity of illness, need for mechanical ventilation, and
heightened mortality rates.
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FIG. 2. Kaplan-Meier curve for probability of ventilator-dependent respiratory failure in the presence or absence of liver injury on
admission.

FIG. 3. Rates of mortality in patients with definitive outcomes according to the presence or absence of liver injury. Twenty patients were
excluded due to continued hospitalization.

In China and Italy, despite an initial decline in
incidence of COVID-19, mortality rates continued to rise.(12) Our study population experienced
22% inpatient mortality (n = 77), with higher death
rates noted in patients with liver injury (28.9% vs.
17.9%; P = 0.018). Our analysis showed that initial
AST elevation was associated with a higher chance
of death, with an AST level of 44 IU/L having a
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specificity of 70% and sensitivity of 50%. For every 1
unit increase in AST, there was an observed increased
risk of death by approximately 1%; the same was not
true for ALT (Table 3). A recent study has shown
that AST elevation is followed by ALT elevation,
which may explain our observation.(13) Higher elevations may correspond to more end-organ damage, which may lead to poorer outcomes. When
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looking at peak liver injury and increased risk of
death, there was a significant association; however,
there remained a considerable number of patients
(n = 20) who were still hospitalized with outcomes
yet to be determined. Given that increased severity
is associated with longer hospitalization,(14) a shortterm follow-up may not be ideal to assess survival in
these patients.
Importantly, transaminase elevation as a surrogate
for liver injury was found to be an independent predictor of acute hypoxic respiratory failure requiring
mechanical ventilation. Studies have shown that respiratory failure is the most common cause of death in
these patients.(2) Therefore, our findings can be useful in identifying those at higher risk for mechanical
ventilation.
TABLE 3. LIVER FUNCTION ABNORMALITIES AS
PREDICTORS OF MORTALITY
Laboratory Value

AUC

Odds
Ratio

95% CI

P Value
0.006

AST (1 unit increase) IU/L

0.59

1.011

1.003, 1.018

ALT (1 unit increase) IU/L

0.50

1.002

0.989, 1.015

0.8

Peak AST (1 unit increase)
IU/L

0.76

1.007

1.003, 1.01

<0.001

Peak ALT (1 unit increase)
IU/L

0.63

1.005

1.002, 1.008

0.003

Total bilirubin (1 unit
increase) mg/dL

0.57

1.997

1.033, 3.862

0.04

Albumin (1 unit increase)
g/dL

0.62

0.5

0.276, 0.845

0.01

Abbreviations: AUC, area under the curve; CI, confidence interval.
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With published data and experience caring for
COVID-19, the medical community has learned
that cytokine-induced inflammatory changes and
secondary infections can complicate the course
of this illness. Procalcitonin on admission, which
is elevated in bacterial infections, was found to
be elevated in 41.3% of patients with liver injury
(P = 0.001). These patients were also more
likely to develop septic shock (23.9% vs. 13.4%;
P = 0.018). This suggests that patients with mild
transaminase elevations are at high risk of secondary
bacterial infection and therefore should be identified for early initiation of antibiotics.
Hypercoagulability has been found to be prevalent
in patients with COVID-19, with many reporting
significant rates of venous thromboembolic events
and clotting of dialysis catheters.(15) Mild elevations
in liver enzymes on presentation were associated with
higher international normalized ratio during hospitalization (73.4% vs. 55.5%; P = 0.001), hinting
that certain patients have a predisposition to liver
failure. However, there is an absence of association
between liver injury and abnormal prothrombin time
and partial thromboplastin time. This suggests that
hypercoagulability is more likely attributed to disseminated intravascular coagulation due to severity of illness rather than liver dysfunction.
We considered whether the presence of liver injury
might vary depending on comorbidities and predisposing factors. Looking at the available data, there
does not appear to be an increased risk of liver injury
during COVID-19 in patients with a history of

FIG. 4. Area under the ROC curve for peak AST, peak ALT, and initial AST levels for predicting mortality. Abbreviation: ROC, receiver
operating characteristic.
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chronic liver disease.(14) We only had 3 patients with
cirrhosis in our study population, and therefore we
could not appropriately analyze this effect. The presence of risk factors for metabolic syndrome (hypertension, diabetes, high BMI, or prior fatty liver on
imaging) did not appear to be more common in
patients who developed liver injury. Similarly, age did
not show any predisposition.
Much attention has focused on home ACEi use
because the virus acts through ACE-2 receptors on
multiple organs, including the liver.(16) In our study,
there was no correlation between the use of ACEi and
liver injury (25% vs. 20.7%; P = 0.47). Taking these
findings into consideration, liver injury appears
to be independent of age, comorbid conditions, ACEi use, or baseline liver function. We suspect that liver injury in COVID-19 is likely related to
virus-induced inflammation rather than exacerbation
of an underlying process.
The degree of transaminase elevation correlated
with the level of inflammation in our patients with
COVID-19. Our study confirmed a demonstrated
association of liver injury with elevated CRP.(14) In
addition, we showed a positive correlation between
liver injury and elevations in D-dimer, ferritin, LDH,
and CPK. In essence, liver function testing can be
used as a surrogate for monitoring of inflammation.
There are currently no proven treatments for
COVID-19, and many options are investigational or
available for compassionate use in those who are critically ill. In this study, patients with liver injury had an
increased likelihood of receiving antibiotics, steroids,
and experimental therapy. Moreover, patients who had
liver injury on admission were noted to have higher
liver enzyme elevations during hospitalization. As some
treatment options may exclude patients with liver dysfunction, knowing which patients are likely to develop
worse transaminases is important as it allows physicians to consider treatment options early if needed.
The main limitation of this study is the retrospective
study design as the data collection is at-risk of human
errors and inaccurate clinical documentation. Some
degree of misclassification of history and symptoms
may be present, although all laboratory tests, including
the SARS-CoV-2 PCR, were done at our hospital.
In conclusion, liver injury seems to be related to the
inflammatory syndrome caused by COVID-19. The
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presence of early liver injury is associated with
increased length of hospitalization, severity of disease,
need for mechanical ventilation, and mortality.
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